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Name(s) of the technology
Multiplexed Tissue Biomarker Imaging
Description of the technology
The detection of structural and functional proteins in
cells within the tumor microenvironment in tissue
samples is achieved by immunolabeling with specific
antibodies. These target proteins are visualized with the
subsequent application of either an enzymatic reaction
that induces chromogen precipitation at the site of
antibody-antigen binding (immunoenzyme method) or
by using fluorescent dyes (e.g., fluorophores, fluorescent
quantum dot nanocrystals) conjugated either to primary
or secondary antibodies (direct or indirect immunofluor-
escence, respectively). In order to maximize the amount
of information that can be acquired from the intact
tumor anatomy as well as to delineate the spatial and
temporal expression information, multiplexed staining
approaches are required. Serial sections lack sufficiency
due to the changing tissue morphology, which prevents
the accurate identification of co-expression and lacks
contextual assessment [1–3]. Advanced multiplexed
immunofluorescence involving iterative stain and strip
procedures can offer significant multiplexing of up to 30
markers [2] and through linear alignment can report on
a single region of interest. Through a more standard
immunoenzyme method, the Tyramide Signal Amplifica-
tion (TSA) technique allows for serial application of
multiple TSA fluorophores on a single tissue section.
This technique can result in multiplexes of up to 7 fluor-
escent dyes, which can be effectively interrogated using
a multispectral microscope [3], Fig. 1.
Type of data obtained/readout
Multiplexed tissue biomarker imaging can enable the com-
prehensive characterization and help to reveal the spatial
relationships between stromal and immune cells within tu-
mors. This method can label up to 6 biomarkers (plus 1
counterstain) in a single tissue section, where cells reside
within a two dimensional relationship. Imaging of multi-
plexed samples uses morphological structures (e.g., tumor-
specific cytokeratin expression) and cellular features (e.g.,
nuclear counterstaining) to identify all cells and their
compartments (nucleus, membrane, and cytoplasm) within
the tissue. The expression information for every biomarker
in the multiplex is exported in table format in delimited .txt
files. Subsequent analysis of the data generated by the
multispectral imaging of multiplexed samples can include:
phenotyping, positivity/negativity counts and H-scoring,
density measurements, and spatial point pattern analyses.
For example, this method allows for the assessment of
FOXP3+ regulatory T cells (Tregs) in tumor tissues, which
have been shown to be associated with adverse prognosis
[4, 5]. In addition, multiplexed analysis of CD3, CD4, CD8,
CD25, FOXP3, and Ki67 would yield a more informative
assessment of Treg and cytotoxic T cell relationship in the
context of CTLA-4 blockade. Moreover, the importance of
the spatial distribution of immune cell infiltrates have been
highlighted in a recent study, showing that the density of
CD8+ T cell infiltrates in the melanoma invasive margin
was the best full predictive parameter of clinical response to
anti-PD-1 immunotherapy [6].
Another useful application would be the assessment of
dendritic and myeloid cell types. For example, dendritic
cells, known to upregulate expression of PD-L1 [7], can be
subdivided into plasmacytoid and myeloid dendritic cells
(pDC and mDC) [8]. In this instance, multiplexed assess-
ment of CD123, CD11c, CD1c and CD141 may aid in the
assessment of dendritic cells within the context of anti-PD1
checkpoint blockade (pDC can be defined through CD11c
(low) and CD123 co-expression, while mDC populations
can be characterized by CD11c and CD1c or CD11c and
CD141 co-expression). Myeloid derived suppressor cells
(MDSC) can also be subdivided into granulocyte and
monocyte lineages, defined by CD11b, CD15, and CD14.
Interestingly, as tumor MDSCs mature, they give rise to
tumor-associated macrophages (TAMs) [9]. TAMs can be
further subdivided into either ‘M1’ or ‘M2’ based on their
differential responses to certain cytokines [10]. In practice,
M1 and M2 can be profiled through CD68 and CD163.
Given the potential role for TAMs in immune suppression
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in classic Hodgkin’s lymphoma (cHL), PD-L1 upregulation
in CD68+ TAMs was recently shown to occur only when
these cells were in close proximity to CD30+ PD-L1+
Reed-Sternberg cells [11]. These findings demonstrate a
potential mechanism for checkpoint blockade, especially in
light of the recent clinical findings of significant clinical
benefit of PD-1 checkpoint blockade in advanced/refractory
cHL [12].
Tumor-draining lymph nodes (TDLNs) have also been
analyzed using this approach. In doing so, immune pro-
file changes within TDLNs have been shown to correlate
with clinical outcome [13–15]. Moreover, in a recent
study, multispectral imaging of CD3, CD8, FOXP3,
CD163, and PD-L1 was used to analyze the tumor
microenvironment as a predictor of the successful gener-
ation and expansion of autologous tumor-reactive tumor
infiltrating lymphocytes (TIL) in melanoma patients.
Using this panel, it was shown that the CD8+:FOXP3+
ratio was a strong predictor of the successful generation
of TIL. In addition, incorporating measures of CD163+
macrophages and the CD8+:PD-L1+ ratio increased the
negative predictive value of this immunoprofile, which, if
validated, could be used as a predictive biomarker to
guide immunotherapy in melanoma patients [16].
Limitations of the approach
Because multiplexed analyses on tissue are not common,
there is risk that a lack of biological information could
result from a multiplexed tissue biomarker imaging of 6
targets. Thus, the results may not correlate with clinical
status or outcome. As a result, this approach could be
rendered insufficient. While deeper fluorescent multi-
plexing has been demonstrated [2, 17], the multiplexed
tissue biomarker imaging method is similar to both
standard immunoenzyme assays and TSA multiplexing.
Therefore, it has a more familiar protocol that could
ease its adoption. More recently, enhanced multiplexing
has been reported with antibodies labeled with metal
isotopes and analyzed by mass cytometry-based ap-
proaches [18, 19]. However, although the morphology
should be preserved with immunolabeling, there are
concerns with using this approach that the preservation
of the discrete microenvironment morphology may be
compromised due to lack of resolution compared to that
which is currently achieved with standard optical
microscopy.
Types of samples needed, special issues
pertaining to samples, and sample analyses
Tissue for this assay can either be fixed in formalin or
flash-frozen. Fixation artifact from formalin-fixed paraf-
fin embedded (FFPE) tissues, such as autofluorescence,
can be abrogated via autofluorescence reduction using
multispectral imaging. In this method, the spectral prop-
erties of autoflourescence can be isolated from all other
relevant informative spectra. Optimization of the multi-
plexed staining is required to avoid spectral crosstalk
that could complicate target unmixing, which is typically
achieved through use of similar tissue types (for many
immune markers, tonsil makes an excellent control tis-
sue). Additional care must also be put into both image
analysis, as well as the downstream data analysis, where
large datasets can be obtained. This would include in-
volving bioinformatic support, where use of advanced
statistical scripting capacity would further interrogation
of multiparametric data, such as that obtained from
spatial point pattern assessments between varied cell
phenotypes.
Level of evidence
Multiplexed tissue biomarker imaging has undergone
many years of development, while recent advances have
been published within the last year [3, 11, 16, 20].
Multispectral tissue imaging has over 700 publications
over the last ten years. The entire application –
multiplexed staining currently up to 7 fluorescent dyes
and multispectral imaging – is offering and will continue
to offer novel, tissue-based contextual clues in cancer
immunology.
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Fig. 1 Multiplexed Lymphocyte Assay in Ovarian Adenocarcinoma.
Representative TSA multiplex of CD3 (green), CD4 (red), CD8
(yellow), CD45RO (magenta), Cytokeratins (brown) and DAPI (blue)
in Ovarian Cancer. Multispectral imaging yields a composite image
where each marker-associated dye can be reliable separated for
accurate phenotypic and expression analyses
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